1. Pharmacovigilance
2. Pathway of PvPI
3. Establishment of PV Programme
in Hospital
4. Establishment of PV Programme
in Industry
5. Contract Research Organization
6. Establishment a National Programme
Physicochemical properties (descriptors) in QSAR.pdf
Establishment of Pharmacovigilance Programme
1. Presented By
Nipun Gupta 810501
Ankush 810512
Naveen 810499
Sudhir 810486
Sumit 810509
B. Pharmacy 8th Semester
2017-2021
Under the Supervision of
Mrs. Roopal Mittal
Assistant Professor (Pharmacology)
R.K.S.D. College of Pharmacy, Kaithal (Haryana)
2. Pharmacovigilance
Pathway of PvPI
Establishment of PV Programme in Hospital
Data Acquisition
Constitution and Functioning
Role of PV in Hospital
Establishment of PV Programme in Industry
Aim
Scientific Character
Pre marketing Surveillance
Post Marketing Surveillance
Contract Research Organization
Identification and Selection
Function of CRO
Establishment a National Programme
Organization
Function
Communication Process and flow of ADR
Contents
3. Pharmacovigilance Science and activities relating to the
Detection
Assessment
Understanding
Prevention
of adverse drug reaction or any other possible drug related problems
4. HISTORY AND DEVELOPMENT
1986 Initiation of PvPI by Name of ADRs Monitoring System
(12 regional center) under supervision of DCGI
1998 India Join WHO PIDM
2005 National Programme for PV launch
2010 PvPI come in force with NCC, AIIMS as well as 22 AMC
2011 NCC, AIIMS transferred to IPC, Ghaziabad
2017 250+ ADR monitoring center
7. Patient
ADE Monitoring
Suspected Medicines
Other Medicines
Risk Factors
Reporter
Data Acquisition/CRF
Reports of Suspected ADRs are taken in case report form CRF which include
minimum following Information
9. Role of PV in Hospital
Role of
PV in
Hospitals
Informatio
n Service
Reachi
ng out
Appraisal
Secondar
y
preventio
n of ADRs
Data
Processi
ng
Hypothesizi
ng
Medicine
Regulatio
n
10. Improve patient care and safety in relation to use of medicine
Protect patient from unnecessary harm by previously unrecognized drug
hazards
Elucidating pre disposing factors
Refuting false safety signal
To quantifying risk in relation to benefit
Aim
13. Post Marketing Surveillance
Spontaneous Reporting
Unsolicited communication by healthcare professionals or consumers to a
company, regulatory authority or other organisation (e.g., WHO, CDSCO etc.)
that describes one or more adverse drug reactions in a patient who was given
one or more medicinal products
Targeted Spontaneous Reporting
To learn more about the ADR profile of specific medicine(s) in your
population Or To estimate the incidence of a known ADR to a specific
medicine in your population
Cohort Study
Cohort study of adverse events associated with one or more monitored medicines.
It is related to class of medicine that has previously caused ADRs Potentially
significant adverse event observed during post-marketing surveillance
Like Retrospective, Prospective
14. Ensure patient safety and
product efficacy
Part of the solution in healthcare delivery
Embrace rnulli0lJannel strategy and digital systems
Drive patient-centric approaches
A new plan for effective Implementation of Pharmacovigilance in the Industry
Future Goal
15. CONTRACT RESEARCH ORGANISATION
A CRO is an organisation contracted by another company to manage and lead the
company's trials, duties and functions.
CRO Identification and Selection
Preparing study designs for each of the research studies to be outsourced.
Determining which CROs should be considered as potential contractors.
Soliciting cost and time proposals which include determining if the CROs understands
the study design and selecting those CRO to be consider further.
Scheduling and conducting site visits to ensure the CROs are qualified.
Negotiating time and cost for completion of research studies.
Selecting the CROs and awarding the contracts for each study to be outsourced.
16. Function of CRO
CRO
Project
Initiation
Concept and
feasibility
Product
Development and
Pre Clinical Testing
Prototyping,
Development,
Validation,
Bench test etc.
Clinical Trial
Protocol
Development,
Initiation &
Monitoring,
Investigation,
Data analysis,
Reporting
Regulatory
Submission
Post-
Marketing
Surveillance
Monitoring
17. Indian
Pharmacopoeia
Commission
NCC PvPI
CDSCO
Headquarter
New Delhi
AEFI and
ITSU
MoHFW
NIB
MoHFW
Noida
Uppsala
Monitoring
Centre,
Sweden
Adverse
Drug
Monitoring
Centre
WHO India
(Country
Office)
National
Health
Programme
MoHFW
Govt. of
India
Establishment of National Pharmacovigilance
Programme
Organization